2020-04-29 16:00Financial Performance - The company's revenue for Q1 2020 was CNY 1,402,313,084.20, representing a 37.06% increase compared to CNY 1,023,118,395.29 in the same period last year[8]. - Net profit attributable to shareholders decreased by 49.65% to CNY 255,292,717.45 from CNY 507,033,390.57 year-on-year[8]. - The net profit excluding non-recurring gains and losses surged by 2,539.57% to CNY 282,711,693.79, compared to CNY 10,710,525.69 in the previous year[8]. - Basic and diluted earnings per share both fell by 49.64% to CNY 0.2047 from CNY 0.4065 year-on-year[8]. - Operating profit decreased by 47.47% to $304.95 million due to an increase in gross profit and a decrease in investment income[29]. - Net profit fell by 48.51% to $254.66 million, primarily due to a reduction in total profit and the exclusion of Junshengtai from the consolidation scope[29]. - The total profit for the current period is CNY 62,850,095.63, compared to a loss of CNY 61,868,580.57 in the previous period, indicating a positive shift in profitability[90]. Cash Flow - The net cash flow from operating activities was negative at CNY -218,059,075.62, worsening by 57.81% from CNY -138,180,573.42 in the same period last year[8]. - Cash flow from operating activities showed a net outflow of $218.06 million, a decrease of 57.81% compared to the previous year, attributed to increased cash payments for goods and services[29]. - The cash flow from operating activities for the current period is CNY 1,271,880,930.82, up from CNY 1,017,727,437.34 in the previous period, reflecting a growth of approximately 25%[94]. - The company reported a total cash outflow from operating activities of 1,298,871,299.47 CNY, significantly higher than 604,629,508.67 CNY in the previous period, highlighting increased operational costs[101]. - The cash inflow from investment activities showed a net inflow of 338,458,770.65 CNY, a significant improvement from -330,273,760.46 CNY in the previous period, indicating better investment management[103]. Assets and Liabilities - Total assets increased by 3.96% to CNY 15,846,107,219.25 from CNY 15,242,205,403.45 at the end of the previous year[8]. - Total liabilities increased by 123.64% to RMB 1,555,851,154.38, primarily due to the issuance of RMB 870 million in corporate bonds during the reporting period[26]. - The company's total equity increased from CNY 7,471,337,346.33 to CNY 7,783,239,153.33, indicating a growth of about 4.2%[67]. - Total current assets increased to CNY 5,999,894,721.87, up by CNY 4,364,030.14 from the previous period[108]. - Total liabilities remained stable at CNY 7,771,095,057.12, with no change reported[111]. Shareholder Information - The top shareholder, Shenzhen Lerun Technology Co., Ltd., holds 38.01% of the shares, with a total of 474,029,899 shares[13]. - The company reported a total of 22,826 common shareholders at the end of the reporting period[13]. Government Support and Subsidies - The company received government subsidies amounting to CNY 15,729,327.98 during the reporting period[8]. - The company reported a significant increase in other income, which rose by 312.15% to RMB 15,729,327.98, driven by an increase in government subsidies received[26]. Research and Development - Research and development expenses decreased by 55.15% to RMB 17,748,891.89, mainly due to the exclusion of Junshengtai from the consolidation scope since March of the previous year[26]. - The company reported a significant increase in research and development expenses to ¥17,748,891.89 from ¥39,576,899.12, indicating a focus on innovation[79]. Market and Investment Activities - The company plans to invest $60 million in TPG Biotechnology Partners V, L.P. to enhance its investment portfolio[32]. - The company has exclusive market licensing rights for RVX-208 in Greater China, with ongoing clinical trials showing promising results[32]. - The company is in the process of applying for overseas listing of its foreign-invested shares (H shares), with the application materials accepted by the China Securities Regulatory Commission on December 28, 2019[36]. Compliance and Commitments - The company has committed to performance compensation obligations in its recent transactions, ensuring accountability for financial performance[41]. - The company has maintained strict adherence to its commitments regarding competition and related party transactions throughout the reporting period[42]. - The company is actively pursuing tax-related commitments, ensuring timely reimbursement of any additional tax liabilities incurred[45].